<DOC>
	<DOCNO>NCT02941926</DOCNO>
	<brief_summary>The purpose Phase IIIb study collect additional safety efficacy data combination ribociclib + letrozole men pre/postmenopausal woman HR+HER2- advance breast cancer .</brief_summary>
	<brief_title>Study Assess Safety Efficacy Ribociclib ( LEE011 ) Combination With Letrozole Treatment Men Pre/Postmenopausal Women With HR+ HER2- aBC</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Male female advance ( locoregionally recurrent metastatic ) breast cancer amenable curative therapy . In case woman , pre/perimenopausal postmenopausal patient allow included study ; menopausal status relevant requirement goserelin use concomitantly ribociclib letrozole . 1 . Postmenopausal status define either : I ) . Prior bilateral oophorectomy OR ii ) . Age ≥ 60 OR iii ) . Age &lt; 60 amenorrhea 12 month ( absence chemotherapy , tamoxifen , toremifen , ovarian suppression ) FSH estradiol postmenopausal range per local normal range . If patient take tamoxifen toremifene age &lt; 60 , FSH plasma estradiol level postmenopausal range per local normal range . Note : For woman therapyinduced amenorrhea , serial measurement FSH and/or estradiol need ensure menopausal status . 2 . Premenopausal status define either : I ) . Patient last menstrual period within last 12 month , OR ii ) . If tamoxifen toremifene within past 14 day , plasma estradiol FSH must premenopausal range per local normal range , OR iii ) . In case therapy induce amenorrhea , plasma estradiol and/or FSH must premenopausal range per local normal range . 3 . Perimenopausal status define neither premenopausal postmenopausal Note : Throughout document , perimenopausal premenopausal status group together refer `` Premenopausal '' Patient histologically and/or cytologically confirm diagnosis estrogenreceptor positive and/or progesterone receptor positive breast cancer local laboratory . Patient HER2negative breast cancer define negative situ hybridization test IHC status 0 , 1+ 2+ . If IHC 2+ , negative situ hybridization ( FISH , CISH , SISH ) test require local laboratory test . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Patient adequate bone marrow organ function define ALL follow laboratory value ( assessed local laboratory ) : Absolute neutrophil count ≥ 1.5 × 10^9/L Platelets ≥ 100 × 10^9/L Hemoglobin ≥ 9.0 g/dL Potassium , sodium , calcium correct serum albumin magnesium within normal limit correct within normal limit supplement first dose study medication INR ≤1.5 Serum creatinine &lt; 1.5 mg/dl creatinine clearance≥50 mL/min In absence liver metastasis , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 2.5 × ULN . If patient liver metastasis , ALT AST &lt; 5 × ULN . Total serum bilirubin &lt; ULN ; total bilirubin ≤ 3.0 × ULN direct bilirubin within normal range patient welldocumented Gilbert 's Syndrome Patient must 12lead ECG ALL follow parameter screen : QTcF interval screen &lt; 450 msec ( use Fridericia 's correction ) Resting heart rate ≥ 50 bpm Patient receive CDK4/6 inhibitor Patient receive prior systemic hormonal therapy advance breast cancer ; one prior regimen chemotherapy treatment metastatic disease permit Note : Patients receive ( neo ) adjuvant therapy breast cancer eligible . If prior neo ( adjuvant ) therapy include letrozole anastrozole disease free interval must great 12 month completion treatment study entry . Patients receive ≤ 28 day letrozole anastrozole advanced disease prior inclusion trial eligible . Any prior ( neo ) adjuvant anticancer therapy prior chemotherapy metastatic disease must stop least 5 halflives 7 day , whichever longer , study inclusion . Patient concurrently use anticancer therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HR-positive HER2-negative</keyword>
	<keyword>advanced breast cancer</keyword>
	<keyword>LEE011</keyword>
	<keyword>ribociclib</keyword>
	<keyword>letrozole</keyword>
	<keyword>goserelin</keyword>
	<keyword>CDK</keyword>
	<keyword>CDK4</keyword>
	<keyword>CDK6</keyword>
	<keyword>CDK4/6</keyword>
	<keyword>Phase IIIb</keyword>
	<keyword>ER-positive</keyword>
	<keyword>PR-positive</keyword>
	<keyword>premenopausal</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>men advance breast cancer</keyword>
</DOC>